New drug combo aims to tackle pancreatic cancer in patients with inherited gene mutations
NCT ID NCT01585805
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing whether adding the drug veliparib to standard chemotherapy (gemcitabine and cisplatin) can shrink tumors or slow cancer growth in people with advanced pancreatic cancer who have BRCA1, BRCA2, or PALB2 gene mutations. The study has two parts: one compares the combination to chemotherapy alone, and the other tests veliparib by itself in patients who have already received treatment. Researchers are looking at tumor response rates and how long patients live without their cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- veliparib (a PARP inhibitor) combined with gemcitabine and cisplatin chemotherapy
- What this could lead to
- If successful, this could point toward a more effective treatment option for pancreatic cancer patients with specific genetic mutations (BRCA/PALB2).
- What could go wrong
- This is a small, early-phase (phase II) trial with only 83 participants. The drug combination may not improve outcomes and could cause additional side effects like bone marrow suppression or fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chaim Sheba Medical Center
Tel Litwinsky, 52621, Israel
-
Ingalls Memorial Hospital
Harvey, Illinois, 60426, United States
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
Mercy Hospital Saint Louis
St Louis, Missouri, 63141, United States
-
Shaare Zedek Medical Center
Jerusalem, 91031, Israel
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Four-Drug cocktail aims to shrink pancreatic tumors before surgery
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors